All News

2068 articles, sorted by publication time.

Biopharmaceuticals · us

Tau Pathway Crosses the Phase 2 Signal Threshold; Diranersen’s Next Question Is Whether It Can Withstand the Enlarged Test of Phase 3

Biogen presented detailed Phase 2 CELIA data at AAIC, allowing Alzheimer’s disease treatment to see another possible path beyond amyloid beta. But the lowest dose was the most striking, while intrathecal administration and long-term benefit mean the Phase 3 trial will not only confirm efficacy, but also measure the boundaries of this scientific hypothesis.